KURA - Kura Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
653.81M
Enterprise Value 3
411.69M
Trailing P/E
N/A
Forward P/E 1
-7.82
PEG Ratio (5 yr expected) 1
-0.72
Price/Sales (ttm)
N/A
Price/Book (mrq)
2.65
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
-6.49

Trading Information

Stock Price History

Beta (3Y Monthly) 2.31
52-Week Change 328.19%
S&P500 52-Week Change 38.78%
52 Week High 321.42
52 Week Low 310.20
50-Day Moving Average 315.26
200-Day Moving Average 316.93

Share Statistics

Avg Vol (3 month) 3265.7k
Avg Vol (10 day) 3271.93k
Shares Outstanding 545.21M
Float 34.07M
% Held by Insiders 119.41%
% Held by Institutions 184.26%
Shares Short (Sep 30, 2019) 42.63M
Short Ratio (Sep 30, 2019) 49.03
Short % of Float (Sep 30, 2019) 49.15%
Short % of Shares Outstanding (Sep 30, 2019) 45.81%
Shares Short (prior month Aug 30, 2019) 42.35M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-20.07%
Return on Equity (ttm)-33.42%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -63.45M
Net Income Avi to Common (ttm)-59.99M
Diluted EPS (ttm)-1.57
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)261.41M
Total Cash Per Share (mrq)5.78
Total Debt (mrq)7.99M
Total Debt/Equity (mrq)3.24
Current Ratio (mrq)23.50
Book Value Per Share (mrq)5.46

Cash Flow Statement

Operating Cash Flow (ttm)-51.89M
Levered Free Cash Flow (ttm)-30.21M